Canaccord Genuity Maintains Buy on Regulus Therapeutics, Raises Price Target to $28

Benzinga · 06/25/2024 14:49
Canaccord Genuity analyst Whitney Ijem maintains Regulus Therapeutics (NASDAQ:RGLS) with a Buy and raises the price target from $11 to $28.